Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating ischemic cerebrovascular disease, and preparation method thereof

A cerebrovascular disease and composition technology, applied in the field of pharmaceutical preparations containing organic active ingredients, can solve problems such as unsatisfactory effects, and achieve the effects of improving bioavailability, good therapeutic effect, and clear ingredients

Inactive Publication Date: 2012-03-28
GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Based on the above, Cyclovirubuxin D and Ligustrazine both have the effect of treating cardiovascular and cerebrovascular diseases, but the effect of using them alone is not ideal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating ischemic cerebrovascular disease, and preparation method thereof
  • Medicinal composition for treating ischemic cerebrovascular disease, and preparation method thereof
  • Medicinal composition for treating ischemic cerebrovascular disease, and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Embodiment 1: (nasal cavity spray)

[0104] 1. Active ingredients: 5g of Cycloviral Buxus D, 30g of Ligustrazine, 2g of Borneol.

[0105] 2. Preparation method:

[0106] (1) Take borneol and dissolve it with an appropriate amount of ethanol to obtain a borneol ethanol solution for later use; take 0.15 g of hydroxypropyl-β-cyclodextrin and add 3 times of distilled water to grind it evenly, add the prepared borneol ethanol solution dropwise, grind and clathrate at room temperature After 1.5 hours, the solution was refrigerated for 24 hours, washed 3 times with ethyl acetate, filtered through a G5 vertical melting funnel, and the filtrate was vacuum-dried to obtain borneol HP-β-cyclodextrin inclusion complex;

[0107] (2) Cyclovirbuxine D and Ligustrazine are dissolved in distilled water, then add the borneol HP-beta-cyclodextrin inclusion compound and ethylparaben 0.1g that step (1) makes successively, fully mix Mix well, add triethanolamine to adjust the pH value to 5....

Embodiment 2

[0108] Embodiment 2: (nasal cavity spray)

[0109] 1. Active ingredients: 7.5g Cycloviral Buxusin D, 40g Ligustrazine, 3.5g Borneol.

[0110] 2. Preparation method:

[0111](1) Take borneol and dissolve it with an appropriate amount of ethanol to obtain borneol ethanol solution for later use; take 0.25 g of hydroxypropyl-β-cyclodextrin and add 3 times of distilled water to grind it evenly, add the prepared borneol ethanol solution dropwise, and grind at room temperature for inclusion After 1.5 hours, the solution was refrigerated for 24 hours, washed 3 times with ethyl acetate, filtered through a G5 vertical melting funnel, and the filtrate was vacuum-dried to obtain borneol HP-β-cyclodextrin inclusion complex;

[0112] (2) Dissolve Cyclovirbuxine D and Ligustrazine in distilled water, then add the borneol HP-β-cyclodextrin inclusion complex prepared in step (1), carbomer 5g, hydroxypropyl methyl Mix 14g of cellulose and 0.2g of potassium sorbate, add triethanolamine to adju...

Embodiment 3

[0113] Embodiment 3: (nasal cavity spray)

[0114] 1. Active ingredients: 10g of Cycloviral Buxusin D, 50g of Ligustrazine, and 5g of Borneol.

[0115] 2. Preparation method:

[0116] (1) Take borneol and dissolve it with an appropriate amount of ethanol to obtain a borneol ethanol solution for later use; take 0.375 g of hydroxypropyl-β-cyclodextrin and add 3 times of distilled water to grind it evenly, add the prepared borneol ethanol solution dropwise, grind and clathrate at room temperature After 1.5 hours, the solution was refrigerated for 24 hours, washed 3 times with ethyl acetate, filtered through a G5 vertical melting funnel, and the filtrate was vacuum-dried to obtain borneol HP-β-cyclodextrin inclusion complex;

[0117] (2) Dissolve Cyclovirbuxine D and Ligustrazine in distilled water, and then add the borneol HP-β-cyclodextrin inclusion compound, Poloxamer 188 14g, Poloxa Mix 18g of M407 and 0.5g of ethyl hydroxybenzoate, add triethanolamine to adjust the pH value...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
boiling pointaaaaaaaaaa
Login to View More

Abstract

The invention relates to a medicinal preparation containing organic active ingredients, in particular to a medicinal composition for treating ischemic cerebrovascular disease. The medicinal composition consists of active ingredients and medicinally acceptable auxiliary materials and is characterized in that the active ingredients consist of the following organic components in part by weight: 5 to10 parts of cyclovirobuxine D, 30 to 50 parts of ligustrazine, and 2 to 5 parts of borneol. In the medicinal composition, the cyclovirobuxine D is compatible with the ligustrazine and has an obvious synergic effect, and pharmacokinetics behaviors of the mechanical composition are changed by using borneol, so that bioavailability of the mechanical composition is improved obviously and the therapeutical effect of the medicine can be exerted conveniently.

Description

technical field [0001] The invention relates to a medical preparation, in particular to a medical preparation containing organic active ingredients. Background technique [0002] Cerebrovascular disease has become one of the serious diseases that seriously endanger the life and health of human beings, especially middle-aged and elderly people. The annual number of patients in my country is 5 to 6 million, and the death toll is about 1.5 million. About 75% of the surviving patients may be left with different degrees of disability, and the severe disability is as high as 40%, which has brought huge economic and spiritual burdens to many families, society and the country. With the aging of my country's population, cerebrovascular diseases are on the rise year by year. At present, in the ranking order of various causes of death in China, cerebrovascular disease is higher than heart disease and cancer, ranking first among the three major causes of death. [0003] The incidence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/57A61K31/4965A61K31/045A61P9/10
Inventor 周莉玲于洋郭丽蓉王利胜周玖瑶
Owner GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com